



Investor Presentation

August 2026



Forward Looking Statement

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements and relate to or are based on estimates regarding market and industry data that Shoulder Innovations, Inc. (the "Company") prepared based on management's knowledge and estimates, together with information obtained from publicly available resources, other third-party sources, the Company's customers and other contacts in the markets in which the Company operates. Management's estimates are derived in part from third party sources and data from the Company's internal research. Although the Company believes that these third-party sources are reliable, it does not guarantee the accuracy or completeness of this information, and the Company has not verified this information. In presenting market and industry data in this presentation, management has made certain assumptions that it believes to be reasonable based on the data available to the Company and other sources, as well as on management's knowledge of, and experience to date in, the industry and markets in which the Company operates. These statements relate to future events or the future performance of the Company, as well as its business strategy and plans and objectives for future operations, and are subject to a number of known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by words such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "may," "will," "could," "predict" and similar expressions or terminology. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission (the "SEC"), and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business related to: our history of significant net losses; failure to manage the growth of our business; our inability to compete successfully against our existing or potential competitors; failure to develop, retain, or expand an effective dedicated commercial leadership team; risks associated with litigation; our dependence upon the adoption of our implant systems by hospitals, ambulatory surgery centers, surgeons and patients; our ability to enhance our implant systems, expand our indications and develop and commercialize additional products in a timely manner; risks associated with our third-party manufacturers and suppliers; demand forecasts for our implant systems; our ability to demonstrate to shoulder specialists or key opinion leaders the merits of our implant systems; federal and state healthcare laws and government regulation and oversight over our devices and operations; our ability to obtain and maintain patent and other intellectual property protection over our products; risks associated with our common stock; and the other important factors described in our most recently filed Annual Report on Form 10-K and subsequent other filings with the Securities and Exchange Commission. The Company has based these forward-looking statements largely on its current expectations, assumptions, estimates and projections. While the Company believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risk and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, the Company assumes no obligation and does not intend to update any of these forward-looking statements after the date of this presentation or to conform these statements to actual results or revised expectations.

In light of the foregoing, you are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.

This presentation shall not constitute and offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Market data and industry information used throughout this presentation are based on management's knowledge of the industry and the good faith estimates of management. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Transforming Shoulder Surgical Care



Experienced Team Redefining Shoulder Surgical Care



Rob Ball
Chief Executive Officer



Jeff Points
Chief Financial Officer



Matt Ahearn
Chief Operating Officer



Dave Blue
*Chief Customer
Experience Officer*



Jon Osborne
Chief Commercial Officer

TORNIER 

imascap

 **DePuy Synthes**
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

CSI.

 **Empi**

 **CliftonLarsonAllen**

Brambles

**Johnson
Controls** 

 **LEANLOGISTICS**
A KEWILL COMPANY

TORNIER 

DVO
Extremity Solutions

 **DePuy Synthes**
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

TORNIER 

Arthrex 

S+N

Proven History of Successful Shoulder Innovation and Commercialization

 **DePuy Synthes**
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

Global Shoulder

*First multi-hundred-million dollar
shoulder arthroplasty product line*



TORNIER 

Simpliciti

*#1 market share shoulder
arthroplasty system worldwide*



TORNIER  / **stryker**

Blueprint

*First pre-operative planning
platform for shoulder*



 **SHOULDER
INNOVATIONS**

 **InSet**

ProVOYANCE




Shoulder Pain is Highly Prevalent with Quality-of-Life-Reducing Impacts

Key Drivers of Shoulder Pain



Osteoarthritis



Rheumatoid Arthritis



Rotator Cuff Tears



Shoulder Fractures

Shoulder Pain is Widespread

1 in 5 People

over 65 suffer from
shoulder pain in the U.S.

8+ Million

annual physician visits
related to shoulder
conditions in the U.S.

38% of Patients¹

with shoulder pain report
inability to perform activities
of daily life

Three Times²

as many total knee
replacements annually
compared to shoulder
arthroplasties in the U.S.

Despite This Prevalence, There Has Been a Historical Underutilization of Surgical Treatments for Shoulder Care

1. Estimated according to a study published in the *Journal of Shoulder and Elbow Surgery*

2. Based on 790,000 total knee replacements done annually in U.S. vs. ~250,000 shoulder arthroplasty procedures (<https://rheumatology.org/patients/joint-replacement-surgery>)


Shoulder Arthroplasty is Our Initial Focus Within Shoulder Surgical Care

Established Surgical Procedures for Reducing Joint Pain and Restoring Shoulder Motion

Osteoarthritis

Anatomic Total Shoulder Arthroplasty (aTSA)


Imitates the natural joint anatomy



Osteoarthritis + Rotator Cuff Deficiency


Reverse Total Shoulder Arthroplasty (rTSA)

Inverts the shoulder anatomy and joint configuration




Shoulder Arthroplasty is One of the Fastest Growing MedTech Segments

Large & Growing TAM



ASC Will Capture Future Growth



>10%

**Historical U.S. Procedure Growth
Between 2019-2024**

~250,000

Procedures in the U.S.⁴

1,800

High-Volume Surgeons⁵

1. Based on management estimates

2. Expected U.S. market growth through 2029

3. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5685972/>

4. Number of shoulder arthroplasty procedures expected in the U.S. in 2025 based on management estimates

5. Defined as U.S. surgeons performing the majority of shoulder arthroplasty procedures

6. Expected global market growth through 2029

7. Expected global market growth through 2030

Significant Limitations of Current Shoulder Arthroplasty Products Provide a Compelling Opportunity

Low Rates of Implant Survivorship
40% of Implants Subject to Revision Surgery¹

Frequent Post-Operative Complications
15% of Subscapularis Tendons Fail Following aTSA²


Imprecise Implant Positioning
As Little as 5 Degrees Off Angle Can Lead to Inferior Outcomes

Burdensome Surgical Workflow
Up to 9 Surgery Trays to Complete a Single Procedure

1. Revision surgery at 10-year follow-up


2. Based on a study published in the *Journal of Shoulder and Elbow Surgery* in which the tendon connecting the subscapularis muscle to the humeral bone is damaged

We Have Developed a Highly Differentiated Ecosystem to Improve Core Components of Shoulder Surgical Care





The InSet Glenoid is the Foundation of Our Implant Systems and Sets a New Standard for Fixation and Stability

Traditional Implant, Sitting on Top of Bony Surface



InSet Glenoid, Sitting Within a Rim of Bone



Complex articular surface further reduces rocking horse motion

Peripheral bone ledge is buttress against rocking horse motion

Enables Improved Fixation Mechanics, More Reliable Implant Placement, Smaller & Simpler Surgical Exposure

Data Demonstrates Significant Clinical Benefits and Improved Patient Outcomes of InSet Glenoid

Pre-Operation



In constant pain and unable to complete daily activities



Pain-free and enjoying better quality of life



+72

Point Score Improvement^{3, 4}

23


Pre-Op ASES¹ Score³

95

Post-Op ASES¹ Score^{3, 4}

Key Clinical Factors

Rotation



Forward Flexion



Pain



Durability



InSet's Differentiation

- ✓ **87% Reduction²**
In "Rocking Horse" Motion
- ✓ **ZERO⁵**
Surgical Complications
- ✓ **ZERO⁵**
Loose Implants
- ✓ **ZERO⁵**
Revision Surgeries
- ✓ **FULL RANGE OF MOTION⁵**
Ability to Raise Arm & Reach Back

InSet's Differentiation Demonstrated by 100% Implant Survivorship⁵ and 87% Reduction in "Rocking Horse" Motion²

InSet Glenoid Technology Leveraged Across a Full Range of Solutions for Both aTSA and rTSA Procedures

InSet aTSA System



InSet rTSA System



Common Post-Operative aTSA Complications Require Surgical Conversion to rTSA


However, Traditional Implants are Not Designed for Replacement, Revision, or rTSA-Conversion Procedures

Traditional Implants....

- ✗ Place the implant stem deep into the humerus
- ✗ Require a high degree of initial bone removal
- ✗ Difficult to replace
- ✗ Not easily convertible from aTSA to rTSA

Post-Operative Complications Can Include...

Overstuffing, shoulder dislocation, humeral fractures, and subscapularis tendon failure




~15% of Subscapularis Tendons Fail
Following an aTSA Procedure^{1, 2}


1. Based on a study published in the *Journal of Shoulder and Elbow Surgery* in which the tendon connecting the subscapularis muscle to the humeral bone is damaged
2. Due to inadequate healing of the tendon post-aTSA procedure

Frequency of Post-Operative aTSA Complications are Driving Significantly Higher rTSA Volumes


Evolution of Shoulder Arthroplasty Procedure Mix



Gradual Market Transition Towards Inlay Reverse Arthroplasty



Onlay
Arthroplasty




Inlay
Arthroplasty


InSet Reverse System Provides Biomechanical Advantages

Engineered to Provide Bone Sparing Implant Options to Achieve Desirable Range of Motion Biomechanics

Traditional Reverse



*Medialized Glenoid-
Medialized Humerus*



41%
of rTSAs Have Limited
Internal Rotation after
Surgery



Biomechanical advantage: a more “anatomic” reverse shoulder construct



Inlay design enables ability to both raise arm **and** reach back (unlike traditional reverse system designs, which can constrain range of motion)

InSet Reverse



*Lateralized Glenoid-
Lateralized Humerus*



Improved Post-Op Internal Rotation



Achieves **desirable impingement free range of motion**; and avoids arm lengthening and overstuffing



Design enables full conversion from anatomic to reverse as needed

InSet Reverse Was Designed to Behave Like an Anatomic Replacement, Maximizing Post-Operative Motion

InSet Stems Are Compatible Across a Full Range of Implant Systems For Interchangeability Between aTSA and rTSA

Three InSet Stem Options

Stemless

70% of primary
aTSA



Short Stem




Long Stem



All InSet Stems are Compatible with Both
aTSA & rTSA Humeral Heads...

...Making Revision / Conversion Surgeries
Straightforward



✓ *Consistent
surgical technique*

✓ *Identical
instruments*

✓ *Similar
biomechanics*

✓ *Interchangeable
with aTSA / rTSA*

Our Capital Efficient Technology Suite Reduces Complexity & Cost...

Status Quo

Up to 9 surgery trays to complete a single procedure



Significant Reduction

in Surgery Tray Usage


- ✓ Full SI product portfolio and all procedures supported by **two instrument trays**
- ✓ Fewer SKUs and trays **reduce the implant footprint** per procedure
- ✓ Decreased capital outlay per procedure enables a **compelling economic value proposition**



ASC Portion of Procedures: ~10% in Dec 2023 to >30% in Dec 2025¹

...and Supports a Broader Market Shift Towards ASC Setting

Transition to the Outpatient Setting



Inpatient Stocking Room



ASC Shelves



ASCs as Site of Care Present Numerous Advantages

- ✓ ASC has emerged as a **cost-efficient site of care delivery for shoulder arthroplasty**
- ✓ **Positive ASC-based clinical outcomes** relative to hospital-based outcomes in shoulder surgery
- ✓ Enables **streamlined workflows, scheduling flexibility, and operational autonomy**
- ✓ Expectation for **future shoulder arthroplasty growth to be largely within ASCs** vs. hospitals
- ✓ **Reimbursement trends** favor the ASC setting – CMS proposed 2027 payments **up 13.6% at ASC**

ProVoyance Enabling Technology Platform: A Core Engagement Center for Our Customers

Pre-Operative *Planning*
Micro-Robotic *Integration*
Intra-Operative *Execution*



- **Hands-on, enhanced** procedural planning performed by surgeons **at the site of care**
- **Next-generation platform currently in development**, to deliver a substantial step-up in software capability and available information tailored to each surgeon's individual technique's and preferences
 - **Engineered for full compatibility with upcoming micro-robotics platform**
 - **Shifts more surgical decision-making to the software/pre-operative planning stage** – OR execution becomes a preconceived resolution of the pre-operating plan, reducing outcome variability

Introducing InSet Neo: A Micro-Robotic Solution for Shoulder Arthroplasty

- ✓ **Fully compatible with next-gen ProVoyance platform**, creating one integrated enabling technology suite
- ✓ **New economic model with no capital burden** – portable, case-by-case deployment that enables a robotics-as-a-service model unavailable with traditional systems
- ✓ **Requires very minimal change to existing surgical techniques** – and no change to bone preparation
- ✓ **Strengthens SI's ability to lead shift to ASCs**, where cost efficiency and ease of implementation are critical
- ✓ **FDA submission planned for first half of 2027**
- ✓ **Robotic training program to begin Q1 2027**, utilizing a “train the trainer” approach

Developing in Partnership With:



**INTERVENTIONAL
SYSTEMS**




Integrated Commercial Approach Accelerates Adoption, Drives Deeper Relationships and Long-Term Retention





Commercial Leadership:

Distributor Management, Target Prospecting, Forecasting, Performance Management

- ✓ Leverage proprietary business intelligence tools and partner with independent distributors for account management




○ Denotes surgeon location and case volumes



CEME:

Key Account Conversions, Utilization Management, Surgeon to Surgeon Training

- ✓ Facilitate rewarding and meaningful experiences for surgeons focused on clinical value



Independent Distributors:

Prospecting, Relationship Management, Servicing, Case Coverage

- ✓ Primarily orthopedic specialists with exclusive agreements to carry InSet as their dedicated shoulder solution

Focused Commercial Approach Targeting the ~1,800 High Volume Surgeons Performing Majority of Procedures

Consistent Innovation & Robust Pipeline of Increasingly Differentiated Technologies

2016 – 2025 Key Launches



Innovation Across New Technologies, I-Series Stems & Expansion, and New Indications

1H 2026

Full launches:

- ✓ InSet 135RFX humeral stem
- ✓ N-22 glenosphere
- ✓ TPS reverse baseplate

2H 2026

Limited launches:

- InSet Clutch guide system
- Subscapularis tendon sparing technique
- Next-generation InSet anatomic glenoid

2027

FDA submissions:

- InSet Neo: Micro-robotic system
- InSet One: additively manufactured iteration of InSet Reverse


Throughout: Development work on next-generation enabling technology platform

- ✓ Multiple programs advancing in parallel across enabling technology, robotics, and new product development
- ✓ Near-term catalysts 2026–2027 across limited releases and FDA submissions, all central to existing clinical focus within shoulder surgical care
- ✓ New third-party collaborations extend innovation beyond core portfolio, providing entry into severe deformity/complex revision cases, plus soft tissue procedures

History of Consistent Above-Market Revenue Growth


Q2 2026 Highlights:

- Revenue of \$17.2M, **56%** Y/Y
- 2,238 implant systems sold, **~50%** Y/Y
- **Continued rapid increase** in new surgeons
- Gross margin of 78.3%, **+210bps** Y/Y
- **\$99.0M** in cash, cash equivalents, and marketable securities



1. Compounded annual growth rate from Q2'24 to Q2'26

Multiple Drivers to Sustain Above-Market Growth



1. The number of shoulder arthroplasty procedures in the United States grew at approximately 10% per year from 2019 to 2024


2. As of December 31, 2025

3. Based on management estimates; defined as U.S. surgeons performing the majority of shoulder arthroplasty procedures


4. As of June 30, 2026

Multiple Initiatives to Drive Profitability

Attractive Gross Margin Profile



Key Profitability Initiatives



Transforming Shoulder Surgical Care





Thank You

